Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $39 | In Stock | |
5 mg | $64 | In Stock | |
10 mg | $97 | In Stock | |
25 mg | $228 | In Stock | |
50 mg | $368 | In Stock | |
100 mg | $593 | In Stock | |
500 mg | $1,250 | In Stock | |
1 mL x 10 mM (in DMSO) | $70 | In Stock |
Description | RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively). RWJ-67657 shows no activity at p38γ and p38δ and shows a cardioprotective effect. |
In vitro | RWJ-67657 suppresses the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells (IC50: 3 nM) and the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (IC50: 13 nM). RWJ67657 (10 μM; 24 hours) reduces colony formation in MCF-7 cells [2][3]. |
In vivo | RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. RWJ-67657 (50 mg/kg; p.o.; once per day for 7 consecutive days) shows an effective anti-inflammatory effect. EPC transplantation plus RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis after diabetic stroke by both improving the functioning of endothelial progenitor cells and reducing inflammation [2][4]. |
Alias | JNJ 3026582 |
Molecular Weight | 425.5 |
Formula | C27H24FN3O |
Cas No. | 215303-72-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (293.77 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.